Coronary Heart Disease Risk in Patients With Stroke or Transient Ischemic Attack and No Known Coronary Heart Disease Findings From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial

被引:48
作者
Amarenco, Pierre [1 ,2 ]
Goldstein, Larry B. [3 ]
Sillesen, Henrik [4 ]
Benavente, Oscar [5 ]
Zweifler, Richard M. [6 ]
Callahan, Alfred, III [7 ]
Hennerici, Michael G. [8 ]
Zivin, Justin A. [9 ]
Welch, K. Michael A. [10 ]
机构
[1] Univ Paris 07, INSERM, U698, F-75018 Paris, France
[2] Univ Paris 07, F-75018 Paris, France
[3] Duke Univ, Durham, NC USA
[4] Univ Copenhagen, Copenhagen, Denmark
[5] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[6] Sentara Heart Hosp, Norfolk, VA USA
[7] Vanderbilt Univ, Nashville, TN USA
[8] Heidelberg Univ, D-6800 Mannheim, Germany
[9] Univ Calif San Diego, San Diego, CA 92103 USA
[10] Franklin Univ, Chicago, MI USA
关键词
atherosclerosis; carotid stenosis; cholesterol; coronary heart disease; lacunar infarcts; prevention; statin; transient ischemic attack; EVENTS; DEATH;
D O I
10.1161/STROKEAHA.109.564781
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Noncoronary forms of atherosclerosis (including transient ischemic attacks or stroke of carotid origin or >50% stenosis of the carotid artery) are associated with a 10-year vascular risk of >20% and are considered as a coronary heart disease (CHD) -risk equivalent from the standpoint of lipid management. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial included patients with stroke or transient ischemic attack and no known CHD regardless of the presence of carotid atherosclerosis. We evaluated the risk of developing clinically recognized CHD in SPARCL patients. Methods-A total of 4731 patients (mean age, 63 years) was randomized to 80 mg/day atorvastatin placebo. The rates of major coronary event, any CHD event, and any revascularization procedure were evaluated. Results-After 4.9 years of follow-up, the risks of a major coronary event and of any CHD end point in the placebo group were 5.1% and 8.6%, respectively. The rate of outcome of stroke decreased over time, whereas the major coronary event rate was stable. Relative to those having a large vessel-related stroke at baseline, those having a transient ischemic attack, hemorrhagic stroke, small vessel stroke, or a stroke of unknown cause had similar absolute rates for a first major coronary event and for any CHD event; transient ischemic attack, small vessel, and unknown cause groups had lower absolute revascularization procedure rates. Major coronary event, any CHD event, and any revascularization procedure rates were similarly reduced in all baseline stroke subtypes in the atorvastatin arm compared with placebo with no heterogeneity between groups. Conclusion-CHD risk can be substantially reduced by atorvastatin therapy in patients with recent stroke or transient ischemic attack regardless of stroke subtype. (Stroke. 2010;41:426-430.)
引用
收藏
页码:426 / 430
页数:5
相关论文
共 14 条
[1]  
AMARENCO P, 2008, EUR HEART J 0603
[2]  
Amarenco P, 2006, NEW ENGL J MED, V355, P549
[3]   Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial [J].
Arima, Hisatomi ;
Tzourio, Christophe ;
Butcher, Ken ;
Anderson, Craig ;
Bousser, Marie-Germaine ;
Lees, Kennedy R. ;
Reid, John L. ;
Omae, Teruo ;
Woodward, Mark ;
MacMahon, Stephen ;
Chalmers, John .
STROKE, 2006, 37 (06) :1497-1502
[4]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[5]   Recurrent stroke and cardiac risks after first ischemic stroke - The Northern Manhattan Study [J].
Dhamoon, MS ;
Sciacca, RR ;
Rundek, T ;
Sacco, RL ;
Elkind, MSV .
NEUROLOGY, 2006, 66 (05) :641-646
[6]   Autopsy prevalence of coronary atherosclerosis in patients with fatal stroke [J].
Gongora-Rivera, Fernando ;
Labreuche, Julien ;
Jaramillo, Arturo ;
Steg, Philippe Gabriel ;
Hauw, Jean-Jacques ;
Amarenco, Pierre .
STROKE, 2007, 38 (04) :1203-1210
[7]   Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study [J].
Hankey, GJ ;
Jamrozik, K ;
Broadhurst, RJ ;
Forbes, S ;
Burvill, PW ;
Anderson, CS ;
Stewart-Wynne, EG .
STROKE, 2000, 31 (09) :2080-2086
[8]   Comparing risks of death and recurrent vascular events between lacunar and non-lacunar infarction [J].
Jackson, C ;
Sudlow, C .
BRAIN, 2005, 128 :2507-2517
[9]   Interrelation between plaque surface morphology and degree of stenosis on carotid angiograms and the risk of ischemic stroke in patients with symptomatic carotid stenosis [J].
Rothwell, PM ;
Gibson, R ;
Warlow, CP .
STROKE, 2000, 31 (03) :615-621
[10]   Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study [J].
Sillesen, H .
CEREBROVASCULAR DISEASES, 2003, 16 (04) :389-395